Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome
Launched by GENNARO SARDELLA · Jan 24, 2013
Trial Information
Current as of May 10, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute coronary syndrome
- • PCI with stent implantation
- • clopidogrel responsiveness
- • \> 75 years of age.
- Exclusion Criteria:
- • history of bleeding diathesis
- • chronic oral anticoagulation treatment
- • contraindications to antiplatelet therapy
- • PCI or coronary artery bypass grafting (CABG) \< 3 months
- • hemodynamic instability
- • platelet count \< 100,000/μl
- • hematocrit \< 30%
- • creatinine clearance \< 25 ml/min
- • Patients with a history of stroke
- • other contraindication for prasugrel administration
- • patients weighing \< 60 kg
- • high on treatment platelet reactivity
About Gennaro Sardella
Gennaro Sardella is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on ethical practices and rigorous scientific methodology, Gennaro Sardella oversees the design, implementation, and management of clinical trials across diverse therapeutic areas. The organization collaborates with healthcare professionals, regulatory agencies, and research institutions to ensure compliance and integrity throughout the research process, ultimately striving to bring effective treatments to market while prioritizing patient safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials